Repligen Corporation
$130.14
▼
-1.96%
2026-04-22 10:12:13
www.repligen.com
NMS: RGEN
Explore Repligen Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.4 B
Current Price
$130.14
52W High / Low
$175.77 / $109.66
Stock P/E
150.55
Book Value
$37.39
Dividend Yield
—
ROCE
1.48%
ROE
2.4%
Face Value
—
EPS
$0.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
2,000
Beta
1.19
Debt / Equity
32.76
Current Ratio
8.37
Quick Ratio
7.12
Forward P/E
48.27
Price / Sales
9.18
Enterprise Value
$6.69 B
EV / EBITDA
53.74
EV / Revenue
9.06
Rating
Buy
Target Price
$183.88
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | LeMaitre Vascular, Inc. | $115 | 44.97 | $2.6 B | 0.87% | 11.72% | 15.8% | $118.01 / $78.01 | $17.28 |
| 2. | AtriCure, Inc. | $28.79 | — | $1.51 B | — | -1.65% | -2.4% | $43.18 / $27.26 | $9.88 |
| 3. | Envista Holdings Corporation | $27.85 | 97.1 | $4.56 B | — | 4.89% | 1.56% | $30.42 / $14.72 | $18.96 |
| 4. | GlucoTrack, Inc. | $0.78 | — | $1.55 M | — | -524.96% | 381.2% | $15.9 / $0.62 | $3.06 |
| 5. | Sharps Technology, Inc. | $1.84 | — | $73.85 M | — | -452.36% | -2.03% | $18.23 / $1.42 | $15.68 |
| 6. | Zentek Ltd. | $0.5 | — | $73.33 M | — | -64.39% | -56.64% | $2.5 / $0.63 | $0.08 |
| 7. | ICU Medical, Inc. | $130.58 | 4,461.76 | $3.27 B | — | 3.08% | 0.04% | $160.29 / $107 | $86.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 197.91 M | 188.81 M | 182.37 M | 169.17 M | 167.55 M | — |
| Operating Profit | 16.35 M | 12.68 M | 5.96 M | 6.58 M | -33.31 M | — |
| Net Profit | 13.29 M | 14.91 M | 14.87 M | 5.83 M | -33.87 M | — |
| EPS in Rs | 0.24 | 0.26 | 0.26 | 0.1 | -0.6 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 738.26 M | 634.44 M | 632.36 M | 801.54 M |
| Operating Profit | 41.56 M | -31.92 M | 17.13 M | 195.94 M |
| Net Profit | 48.89 M | -25.51 M | 35.6 M | 185.96 M |
| EPS in Rs | 0.87 | -0.45 | 0.63 | 3.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.95 B | 2.83 B | 2.83 B | 2.53 B |
| Total Liabilities | 843.57 M | 856.95 M | 866.34 M | 620.9 M |
| Equity | 2.11 B | 1.97 B | 1.96 B | 1.91 B |
| Current Assets | 1.14 B | 1.07 B | 1.11 B | 998.12 M |
| Current Liabilities | 135.83 M | 126.79 M | 164.94 M | 404.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 117.42 M | 175.39 M | 113.92 M | 172.08 M |
| Investing CF | -298.47 M | -86.38 M | -123.28 M | -233.24 M |
| Financing CF | -15.21 M | -82.9 M | 248.96 M | -13.34 M |
| Free CF | 91.69 M | 142.49 M | 74.93 M | 38.74 M |
| Capex | -25.73 M | -32.91 M | -38.99 M | -133.35 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 16.36% | 0.33% | -21.11% | — |
| Earnings Growth % | 291.64% | -171.68% | -80.86% | — |
| Profit Margin % | 6.62% | -4.02% | 5.63% | 23.2% |
| Operating Margin % | 5.63% | -5.03% | 2.71% | 24.45% |
| Gross Margin % | 52.32% | 43.29% | 44.03% | 56.85% |
| EBITDA Margin % | 24.5% | 12.65% | 22.98% | 34.6% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.